Skytrofa

Active Ingredient(s): Lonapegsomatropin-tcgd
FDA Approved: * August 25, 2021
Pharm Company: * ASCENDIS PHARMA ENCOCRINOLOGY DIV A/S
Category: Growth Hormone Treatment

* This drug may consist of multiple approval dates, manufacturers, or distributors. If applicable, they would be listed below under "NDC Database Records".



Skytrofa Overview

Lonapegsomatropin, sold under the brand name Skytrofa, is a human growth hormone used for the treatment of growth hormone deficiency.[1] Lonapegsomatropin is a prodrug of somatropin.[1] Lonapegsomatropin was approved for medical use in the United States in August 2021.[1][2][3] Contents 1 Medical uses 2 References 3 Further reading 4 External links Medical uses Lonapegsomatropin is a growth hormone therapy ...

Read more Skytrofa Details
Details May Include Instructions, Side Effects, Interactions, Etc. Drug monograph is from Wikipedia. All text is available under the terms of the GFDL (GNU Free Documentation License). Source: en.wikipedia.org/wiki/Lonapegsomatropin

Recent Skytrofa Forums:

Be the first to start a discussion about this drug.

Possible Dosages for this and Related Drugs:

Lonapegsomatropin-tcgd
  • Injection: 11mg, 13.3mg, 3.6mg, 3mg, 4.3mg, 5.2mg, 6.3mg, 7.6mg, 9.1mg
Note: Above list includes dosages for all drugs with the same combination of active ingredients.

Other drugs which contain Lonapegsomatropin-tcgd or a similar ingredient: (1 result)